JPMorgan Chase & Co. Lowers Position in Perspective Therapeutics, Inc. $CATX

JPMorgan Chase & Co. cut its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 41.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 436,357 shares of the company’s stock after selling 311,710 shares during the quarter. JPMorgan Chase & Co.’s holdings in Perspective Therapeutics were worth $1,497,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of CATX. Bank of America Corp DE lifted its position in Perspective Therapeutics by 139.9% during the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock valued at $2,695,000 after purchasing an additional 458,323 shares in the last quarter. Patient Square Capital LP purchased a new position in Perspective Therapeutics during the third quarter valued at $1,198,000. UBS Group AG lifted its position in Perspective Therapeutics by 72.0% during the third quarter. UBS Group AG now owns 641,143 shares of the company’s stock valued at $2,199,000 after purchasing an additional 268,433 shares in the last quarter. Geode Capital Management LLC lifted its position in Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after purchasing an additional 188,887 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Perspective Therapeutics by 227.1% during the second quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company’s stock valued at $835,000 after purchasing an additional 168,448 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX opened at $4.37 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.17 and a quick ratio of 5.17. The business’s 50-day simple moving average is $4.83 and its two-hundred day simple moving average is $3.53. Perspective Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. On average, equities research analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CATX shares. Royal Bank Of Canada lowered their target price on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. Piper Sandler started coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 target price on the stock. UBS Group lifted their target price on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 18th. Finally, BTIG Research reiterated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.